Loading
ALC1 loosens packed DNA at sites of damage so it can be repaired. Cancers that already lack the BRCA repair route, such as some breast and ovarian cancers, lean on it, and losing it made such cells far more sensitive to PARP inhibitors in the laboratory; an ALC1 inhibitor is in early trials. This dossier gathers the 1 product (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
ATP-dependent chromatin remodeller whose activity is switched on by binding histones that carry poly(ADP-ribose) at DNA lesions (UniProt Q86WJ1).
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"ALC1" OR ABSTRACT:"ALC1" OR TITLE:"CHD1L" OR ABSTRACT:"CHD1L" OR TITLE:"amplified in liver cancer 1" OR ABSTRACT:"amplified in liver cancer 1" OR TITLE:"chromodomain helicase DNA binding protein 1 like" OR ABSTRACT:"chromodomain helicase DNA binding protein 1 like") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALC1 (CHD1L), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/alc1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/alc1.json. Licence CC BY-NC 4.0.